Bhat KM, Setaluri V. Microtubule-associated proteins as targets in cancer chemotherapy. Clin Cancer Res. 2007;13:2849–54.

Article  CAS  PubMed  Google Scholar 

Kaur R, Kaur G, Gill RK, Soni R, Bariwal J. Recent developments in tubulin polymerization inhibitors: an overview. Eur J MedChem. 2014;87:89–124.

Article  CAS  Google Scholar 

Wang XY, Gigant B, Zheng X, Chen Q. Microtubule-targeting agents for cancer treatment:seven binding sites and three strategies. Medcomm-oncology. 2023;2:e46.

Article  CAS  Google Scholar 

Prota AE, Bargsten K, Northcote PT, Marsh M, Altmann KH, Miller JH, et al. Structural basis of microtubule stabilization by laulimalide and peloruside A. Angew ChemInt Ed Eng. 2014;53:1647–51.

Article  Google Scholar 

Yang J, Wang Y, Wang T, Jiang J, Botting CH, Liu H, et al. Pironetin reacts covalently with cysteine-316 of α-tubulin to destabilize microtubule. Nat Commun. 2016;7:12103.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cui H, Arnst K, Miller DD, Li W. Recent advances in elucidating paclitaxel resistance mechanisms in non-small cell lung cancer and strategies to overcome drug resistance. Curr Med Chem. 2020;27:6573–95.

Article  CAS  PubMed  Google Scholar 

Cui Y, Zhang J, Zhang G. The potential strategies for overcoming multidrug resistance and reducing side effects of monomer tubulin inhibitors for cancer therapy. Curr Med Chem. 2024;31:1874–95.

Article  CAS  PubMed  Google Scholar 

Zhu H, Wang J, Zhang Q, Pan X, Zhang J. Novel strategies and promising opportunities for targeted protein degradation: an innovative therapeutic approach to overcome cancer resistance. PharmacolTher. 2023;244:108371.

CAS  Google Scholar 

Dong YW, Ma TT, Xu T, Feng ZY, Li YG, Song LL, et al. Characteristic roadmap of linker governs the rational design of PROTACs. Acta Pharmaceutica Sin B. 2024;14:4266–95.

Article  CAS  Google Scholar 

Salami J, Alabi S, Willard RR, Vitale NJ, Wang J, Dong H, et al. Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance. Commun Biol. 2017;1:100.

Article  Google Scholar 

Sun Y, Ding N, Song Y, Yang Z, Liu W, Zhu J, et al. Degradation of Bruton’s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas. Leukemia. 2019;33:2105–10.

Article  PubMed  Google Scholar 

Yang Y, Gao H, Sun X, Sun Y, Qiu Y, Weng Q, et al. Global PROTAC toolbox for degrading BCR-ABL overcomes drug-resistant mutants and adverse effects. J Med Chem. 2020;63:8567–83.

Article  CAS  PubMed  Google Scholar 

Mi L, Gan N, Cheema A, Dakshanamurthy S, Wang X, Yang DCH, et al. Cancer preventive isothiocyanates induce selective degradation of cellular alpha- and beta-tubulins by proteasomes. J BiolChem. 2009;284:17039–51.

CAS  Google Scholar 

Harris G, Schaefer KL. The microtubule-targeting agent T0070907 induces proteasomal degradation of tubulin. Biochem Biophys Res Commun. 2009;388:345–9.

Article  CAS  PubMed  Google Scholar 

Yang J, Li Y, Yan W, Li W, Qiu Q, Ye H, et al. Covalent modification of Cys-239 in beta-tubulin by small molecules as a strategy to promote tubulin heterodimer degradation. J Biol Chem. 2019;294:8161–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alhosin M, Ibrahim A, Boukhari A, Sharif T, Gies JP, Auger C, et al. Anti-neoplastic agent thymoquinone induces degradation of alpha and beta tubulin proteins in human cancer cells without affecting their level in normal human fibroblasts. Invest N Drugs. 2012;30:1813–9.

Article  CAS  Google Scholar 

Li Y, Liu Y, Zhu Z, Yan W, Zhang C, Yang Z, et al. Structure-based design and synthesis of n-substituted 3-amino-beta-carboline derivatives as potent alphabeta-tubulin degradation agents. J Med Chem. 2022;65:2675–93.

Article  CAS  PubMed  Google Scholar 

Gasic I, Groendyke BJ, Nowak RP, Yuan JC, Kalabathula J, Fischer ES, et al. Tubulin resists degradation by cereblon-recruiting PROTACs. Cells. 2020;9:1–14.

Article  Google Scholar 

Yang H, Qin J, Pei Y, Guan S, Zhao M, Wang Y, et al. Discovery of the cereblon-recruiting tubulin PROTACs effective in overcoming Taxol resistance in vitro and in vivo. Eur J Med Chem. 2024;265:116067.

Article  CAS  PubMed  Google Scholar 

Shen CH, Shee JJ, Wu JY, Lin YW, Wu JD, Liu YW. Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model. Br J Pharmacol. 2010;160:2008–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang X, Huang R, Gou S, Wang Z, Liao Z, Wang H. Combretastatin A-4 analogue: a dual-targeting and tubulin inhibitor containing antitumor pt(iv) moiety with a unique mode of action. Bioconjug Chem. 2016;27:2132–48.

Article  CAS  PubMed  Google Scholar 

Petzold G, Fischer ES, Thoma NH. Structural basis of lenalidomide-induced CK1alpha degradation by the CRL4(CRBN) ubiquitin ligase. Nature. 2016;532:127–30.

Article  CAS  PubMed  Google Scholar 

Stanton RA, Gernert KM, Nettles JH, Aneja R. Drugs that target dynamic microtubules: a new molecular perspective. Med Res Rev. 2011;31:443–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tang H, Liang Y, Cheng J, Ding K, Wang Y. Bifunctional chiral selenium-containing 1,4-diarylazetidin-2-ones with potent antitumor activities by disrupting tubulin polymerization and inducing reactive oxygen species production. Eur J Med Chem. 2021;221:113531.

Article  CAS  PubMed  Google Scholar 

Etienne-Manneville S. Actin and microtubules in cell motility: which one is in control?. Traffic. 2004;5:470–7.

Article  CAS  PubMed  Google Scholar 

Neves MA, Totrov M, Abagyan R. Docking and scoring with ICM: the benchmarking results and strategies for improvement. J Comput Aided Mol Des. 2012;26:675–86.

Article  CAS  PubMed  PubMed Central  Google Scholar